Medtronic Reports $36.36B FY2026 Revenue as EPS Shows Significant Growth

Reflecting the resilience of the med-tech sector amid macroeconomic shifts, Medtronic has reported its financial results for the full fiscal year 2026. The company achieved total revenue of $36.36 billion, while diluted earnings per share (EPS) reached $3.73, marking a significant year-over-year increase. To navigate rising headwinds, the firm is actively implementing restructuring and supply chain initiatives designed to mitigate the impact of production costs and tariffs.

This growth occurs as industry peers show mixed performance; per market data, competitors like Abbott Laboratories and Boston Scientific have maintained steady valuations. Industry analysis indicates that international expansion and surgical innovation remain primary revenue drivers, mirroring Medtronic's strategic focus which helped bolster margins despite global inflationary pressures and supply chain constraints cited in recent sector reports.

Regarding stock performance, MDT stood at $81.32 (at close 2026-06-16), trading within a range of $80.6 to $81.63 during the session. Investors are watching the $80.6 support level closely, while monitoring the economic calendar for upcoming inflation data and central bank commentary that could influence healthcare sector sentiment in the coming week.